Login
institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published • loading... • Updated

NeuroSense's ALS Drug Achieves Breakthrough: 40% Slower Decline, 74% Better Survival as Phase 3 Nears

Summary by stocktitan.net
Latest Phase 2b data reveals PrimeC's potential as ALS game-changer with 40% slower decline. Manufacturing scaled for Phase 3 trial launch. See full results.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

2 Articles

stocktitan.netstocktitan.net

NeuroSense's ALS Drug Achieves Breakthrough: 40% Slower Decline, 74% Better Survival as Phase 3 Nears

Latest Phase 2b data reveals PrimeC's potential as ALS game-changer with 40% slower decline. Manufacturing scaled for Phase 3 trial launch. See full results.

Read Full Article
ALS News TodayALS News Today

Plans in place for Phase 3 testing of ALS therapy NP001 next year

Open the article to view the coverage from ALS News Today

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

ALS News Today broke the news in on Friday, August 1, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

News
For You
SearchBlindspotLocal